In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Aerie Pharma (AERI – Research Report), with a price target of $28.00. The company’s shares closed last Thursday at $19.25, close to its 52-week high of $19.42.
According to TipRanks.com, Yang has 0 stars on 0-5 stars ranking scale with an average return of -5.6% and a 33.3% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals, Sarepta Therapeutics, and Magenta Therapeutics.
Currently, the analyst consensus on Aerie Pharma is a Strong Buy with an average price target of $27.25, implying a 40.1% upside from current levels. In a report issued on February 19, Needham also assigned a Buy rating to the stock with a $26.00 price target.
Based on Aerie Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $24.68 million and GAAP net loss of $46.14 million. In comparison, last year the company earned revenue of $24.66 million and had a GAAP net loss of $55.06 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.